The Role of Therapeutic Monitoring of Everolimus in Solid Organ Transplantation
Vincent H Mabasa, Mary H. H. Ensom
Therapeutic Drug Monitoring, 2005
Abstract
This research paper explore the methodology and findings associated with Therapeutic Drug Monitoring. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).
Related Research
- Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients 2019
- Stability of Sirolimus and Everolimus Measured by Immunoassay Techniques in Whole Blood Samples from Kidney Transplant Patients 2008
- Conversion From Sirolimus to Everolimus in Long-Term Liver Graft Recipients 2017
- Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus 2020
- Conversion between sirolimus and everolimus in heart transplant recipients 2023
References
- Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study 2004
- Rapid Liquid Chromatography–Tandem Mass Spectrometry Routine Method for Simultaneous Determination of Sirolimus, Everolimus, Tacrolimus, and Cyclosporin A in Whole Blood 2002
- Entry‐into‐human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients 1999
- Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients Based on Exposure–Effect Modeling 2004
- Validation of a Practical Liquid Chomatography With Ultraviolet Detection Method for Quantification of Whole-Blood Everolimus in a Clinical TDM Laboratory 2005